Empowering Myeloid Cells to Better Address Unmet Clinical Needs

To maximize the drugability potential, we target approaches to improve clinical benefits based on reverse translational science and emerging biology of the tumor microenvironment.

  • (Reverse)Translational Science

    Clinical Experience   Basic Research

    Identification of patients' unmet needs, novel targets, pathways, and mechanisms.

  • Drug Discovery & Development

    Myeloid Engager

    Validation of target, mechanism of action, and proof of concept, and development of novel engager with high potency and good safety profile.

  • Immunotherapy

    Clinical Benefit

    Boosting of anti-tumor immunity to fight against cancer.

Our Myeloid Engager Platform

Novel Mechanism of Action

Direct engagement of myeloid cells with target cells.

Activation of killing mechanism (such as phagocytosis) by myeloid cells directed towards target cells.

Stimulation of myeloid cells to release minimal cytokines and chemokines known to reprogram and reset the immunosuppressive tumor microenvironment and enhance cytotoxic T cell function.

Cross presentation of tumor neoantigens and activation of tumor-specific T cells to support durable anti-tumor immune responses and immunological memory.

We have a global character of innateness
in our science & culture.

Latest News

LTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat Cancer and Autoimmune Diseases

REDWOOD CITY, Calif. and SHENZHEN, China May 31, 2023

REDWOOD CITY, Calif. and SHENZHEN, China -- May 31, 2023 -- LTZ Therapeutics – an immunotherapy-focused biotech company – today announced it has raised over $10 million in pre-A+ financing led by Qiming Venture Partners, with co-investor participation from Shunwei Capital, Lihehongxin Venture Capital Partnership and K2 Venture Partners. The closing of this round brings LTZ’s total funding to approximately $30 million since the company was founded in 2022. The proceeds from this round of funding will be used to continue establishing the company’s platform and pipeline and building LTZ's global operations team.

Follow Us
  • Stay ln Touch

    General Inquiries


    Business Development

  • Locations

    Redwood City, USA

    1100 Island Dr., Suite 103, Redwood City, CA, 94065

    Shenzhen, China

    Room 209, Scientific Research Building, Tsinghua Hi-Tech Park, Nanshan District, Shenzhen, 518057

@ 2024 LTZ Therapeutics Inc., All Rights Reserved.

Privacy Policy | Term of Use | Contact Us